4D Molecular Therapeutics (FDMT) Common Equity (2019 - 2025)
Historic Common Equity for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $369.0 million.
- 4D Molecular Therapeutics' Common Equity fell 3326.99% to $369.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $369.0 million, marking a year-over-year decrease of 3326.99%. This contributed to the annual value of $510.6 million for FY2024, which is 6587.33% up from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Common Equity stood at $369.0 million, which was down 3326.99% from $420.9 million recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Common Equity peaked at $600.6 million during Q1 2024, and registered a low of $218.6 million during Q1 2023.
- For the 5-year period, 4D Molecular Therapeutics' Common Equity averaged around $356.4 million, with its median value being $319.1 million (2021).
- Per our database at Business Quant, 4D Molecular Therapeutics' Common Equity skyrocketed by 17472.3% in 2024 and then crashed by 3326.99% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Common Equity stood at $319.1 million in 2021, then fell by 27.5% to $231.3 million in 2022, then surged by 33.07% to $307.8 million in 2023, then surged by 65.87% to $510.6 million in 2024, then fell by 27.74% to $369.0 million in 2025.
- Its Common Equity was $369.0 million in Q3 2025, compared to $420.9 million in Q2 2025 and $469.7 million in Q1 2025.